Pancreatic Cancer Market Regional Analysis:
North American Market Insights
The pancreatic cancer market in North America is projected to be the largest shareholder, accounting for 32% throughout the analyzed timeframe. The region’s leadership is attributed majorly to the increasing adoption of new technologies to deliver better cancer care and outcomes. Ongoing advancements and improved public access to accurate diagnosis and early intervention are creating a progressive atmosphere in this landscape, attracting global leaders to participate. In addition, the enlarging patient pool, where the rate of PC incidence was 8.0 per 100,000 till 2023 (NLM), is also fueling demand in this sector. Furthermore, the region’s dominant captivity in the precision oncology industry, poised to capture 43.0% by 2035, is making North America the hub of innovation for this field.
The U.S. is augmenting the market with several driving factors such as the enlarging patient pool, supportive regulatory framework, and increasing R&D activities. As per a 2023 NLM article, PC is the 3rd leading cause of mortality in this country, accounting for 62,200 and 48,800 new and death cases each year, respectively. Simultaneously, in February 2024, the FDA provided marketing clearance to the combination chemotherapy, NALIRIFOX, for use as a first-line solution for metastatic pancreatic cancer with no previous treatment received. On the other hand, in January 2024, PanCAN collaborated with the Global Coalition for Adaptive Research (GCAR) to leverage the capabilities of its adaptive clinical trial platform, Precision Promise, escalation R&D to create new therapeutics for PC.
APAC Market Insights
Asia Pacific is predicted to hold a 28% share of the global pancreatic cancer market by the end of 2035. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is propelling its augmentation. Its strong emphasis on pharmaceutical advances and oncological clinical trials to develop new drugs is also estimated to magnify its significance. In this regard, in September 2024, Eisai Co., in collaboration with the National Cancer Center of Japan, announced the commencement of investigator-initiated clinical studies to establish an anti-cancer drug discovery and development system. This initiation was based on the recent findings, demonstrating 38.1% tumor shrinkage in various malignancies, including pancreatic cancer, with the use of a targeted protein degrader, E7820.
India is emerging as a lucrative trading landscape and a leading innovator in the market. The nationwide presence of high-risk patients is enlarging the consumer base in this field, attracting global leaders to invest in this country. Out of all countries, this country marked the 2nd highest rise in incidence, 3.7%, in the world among females in 2022, as per NLM study. Thus, with an intention to expand its portfolio, Servier launched a new treatment option, Onivyde (nanoliposomal irinotecan), for metastatic PC residents in India, in October 2024. Moreover, this scenario indicates a steadily growing demand and a progressive clinical development culture in this field.
